Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zai Lab Ltd ADR
(NQ:
ZLAB
)
17.92
-1.14 (-5.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zai Lab Ltd ADR
< Previous
1
2
3
4
Next >
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
April 27, 2023
YL212 expands Zai Lab’s lung cancer franchise and enriches its global oncology pipeline with a potential first-in-class ADC
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
April 20, 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
April 11, 2023
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531)
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
March 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
January 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
January 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
January 03, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in January Investor Conferences
December 20, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
December 15, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
December 05, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates
November 09, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2022
Poster presentations will highlight Zai’s key internal pipeline programs, ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
November 08, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in November Investor Conferences
October 31, 2022
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 18, 2022
-- Company to Host Conference Call and Webcast on November 10, 2022, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Launches its first Trust Report
October 14, 2022
Outlines Company’s ESG Strategy through its Trust for Life Commitments
From
Zai Lab Limited
Via
GlobeNewswire
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
September 27, 2022
From
Seagen Inc.
Via
Business Wire
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
June 03, 2022
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.